These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32753938)

  • 1. Reducing Episodic Cluster Headaches: Focus on Galcanezumab.
    Pellesi L; De Icco R; Al-Karagholi MA; Ashina M
    J Pain Res; 2020; 13():1591-1599. PubMed ID: 32753938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galcanezumab: a humanized monoclonal antibody for the prevention of migraine and cluster headache.
    Ossipov MH; Raffa RB; Pergolizzi JV
    Drugs Today (Barc); 2020 Jan; 56(1):5-19. PubMed ID: 32055802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug profile: galcanezumab for prevention of cluster headache.
    Mudugal D; Monteith TS
    Expert Rev Neurother; 2021 Feb; 21(2):145-155. PubMed ID: 33206562
    [No Abstract]   [Full Text] [Related]  

  • 4. CGRP pathway monoclonal antibodies for cluster headache.
    Chan C; Goadsby PJ
    Expert Opin Biol Ther; 2020 Aug; 20(8):947-953. PubMed ID: 32241175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache.
    Scott LJ
    Drugs; 2020 Jun; 80(9):893-904. PubMed ID: 32504377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-monthly galcanezumab for the prevention of migraine in adults: an evidence-based descriptive review and potential place in therapy.
    Lupi C; Guerzoni S; Negro A; Benemei S
    Ther Clin Risk Manag; 2019; 15():557-569. PubMed ID: 31043785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials.
    Yang Y; Wang Z; Gao B; Xuan H; Zhu Y; Chen Z; Wang Z
    J Headache Pain; 2020 Feb; 21(1):14. PubMed ID: 32046655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Galcanezumab for episodic and chronic cluster headache].
    Pohl H; Holle-Lee D; Broicher SD; Schwerdtner I; Gantenbein AR; Gaul C
    Schmerz; 2023 Jun; 37(3):168-174. PubMed ID: 35476143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment.
    Dodick DW; Goadsby PJ; Lucas C; Jensen R; Bardos JN; Martinez JM; Zhou C; Aurora SK; Yang JY; Conley RR; Oakes T
    Cephalalgia; 2020 Aug; 40(9):935-948. PubMed ID: 32050782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of galcanezumab as a treatment of refractory episodic and chronic cluster headache: Case series and narrative review.
    Membrilla JA; Torres-Ferrus M; Alpuente A; Caronna E; Pozo-Rosich P
    Headache; 2022 Nov; 62(10):1395-1405. PubMed ID: 36321947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trial of Galcanezumab in Prevention of Episodic Cluster Headache.
    Goadsby PJ; Dodick DW; Leone M; Bardos JN; Oakes TM; Millen BA; Zhou C; Dowsett SA; Aurora SK; Ahn AH; Yang JY; Conley RR; Martinez JM
    N Engl J Med; 2019 Jul; 381(2):132-141. PubMed ID: 31291515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.
    Yuan H; Spare NM; Silberstein SD
    Headache; 2019 Jul; 59 Suppl 2():20-32. PubMed ID: 31291020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventive therapy with galcanezumab for two consecutive cluster bouts in patients with episodic cluster headache: an observational multicenter study.
    Hong Y; Kang MK; Moon HS; Kim BK; Cho SJ
    J Headache Pain; 2023 Oct; 24(1):136. PubMed ID: 37817084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.
    Skljarevski V; Oakes TM; Zhang Q; Ferguson MB; Martinez J; Camporeale A; Johnson KW; Shan Q; Carter J; Schacht A; Goadsby PJ; Dodick DW
    JAMA Neurol; 2018 Feb; 75(2):187-193. PubMed ID: 29255900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CGRP-Targeted Therapy for Episodic and Chronic Cluster Headache.
    Chen ST; Wu JW
    Curr Pain Headache Rep; 2022 Sep; 26(9):667-675. PubMed ID: 35881279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Galcanezumab for the prevention of cluster headache.
    Giani L; Proietti Cecchini A; Leone M
    Expert Opin Biol Ther; 2020 Oct; 20(10):1133-1142. PubMed ID: 32702245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.
    Skljarevski V; Matharu M; Millen BA; Ossipov MH; Kim BK; Yang JY
    Cephalalgia; 2018 Jul; 38(8):1442-1454. PubMed ID: 29848108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data.
    Khan S; Olesen A; Ashina M
    Cephalalgia; 2019 Mar; 39(3):374-389. PubMed ID: 29110503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.